Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 713,526 | 197,486 | 335,639 | 298,190 | 433,584 |
| Marketable Securities | 488,007 | 568,034 | 477,777 | 365,088 | 321,646 |
| Receivables | 23,093 | 27,762 | 23,366 | 154,877 | 32,844 |
| Inventories | 13,048 | 14,457 | 11,061 | 11,375 | 11,546 |
| TOTAL | $1,295,304 | $872,003 | $906,039 | $894,318 | $851,017 |
| Non-Current Assets | |||||
| PPE Net | 73,515 | 48,773 | 48,339 | 47,596 | 44,348 |
| Investments And Advances | 165,881 | 129,320 | 144,288 | 77,131 | 32,926 |
| Intangibles | 175,519 | 175,600 | 175,681 | 173,406 | 173,406 |
| Other Non-Current Assets | 49,336 | 42,689 | 39,694 | 40,689 | 33,799 |
| TOTAL | $464,251 | $396,382 | $408,002 | $338,822 | $284,479 |
| Total Assets | $1,759,555 | $1,268,385 | $1,314,041 | $1,233,140 | $1,135,496 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 12,923 | 10,850 | 9,014 | 14,405 | 12,871 |
| Accrued Expenses | 108,491 | 79,653 | 71,887 | 67,719 | 83,194 |
| Other current liabilities | 59,219 | 102,898 | 131,570 | 107,247 | N/A |
| TOTAL | $189,609 | $201,186 | $219,729 | $196,858 | $103,300 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 382,265 | 367,702 | 365,419 | 393,830 | 345,126 |
| TOTAL | $415,571 | $401,008 | $398,725 | $427,136 | $378,432 |
| Total Liabilities | $605,180 | $602,194 | $618,454 | $623,994 | $481,732 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 66,949 | 61,045 | 60,590 | 59,749 | 57,889 |
| Common Shares | 67 | 61 | 60 | 59 | 58 |
| Retained earnings | -1,619,576 | -1,595,565 | -1,526,720 | -1,552,035 | -1,433,010 |
| Other shareholders' equity | 689 | 1,013 | 1,284 | -1,545 | -147 |
| TOTAL | $1,154,375 | $666,191 | $695,587 | $609,146 | $653,764 |
| Total Liabilities And Equity | $1,759,555 | $1,268,385 | $1,314,041 | $1,233,140 | $1,135,496 |